Eilean Therapeutics LLC, a biopharmaceutical company dedicated to developing best-in-class and first-in-class small-molecule therapies targeting genetic escape mutations in cancer and advancing innovative treatments for chronic inflammatory and immune diseases, today announced the presentation of in vivo data for its first-in-class MALT1 degrader, TE205, as a disease-modifying therapy for ulcerative colitis at the 4th International Conference on Microbiology and Immunology in Las Vegas, Nevada.
Preclinical Findings
In preclinical studies, TE205 demonstrated a robust and multifaceted immunomodulatory effect in the DSS-induced colitis model, achieving both structural and functional restoration of intestinal integrity.
By selectively degrading MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1), TE205 effectively:
- Suppressed NF-κB signaling and pro-inflammatory cytokine production,
- Rebalanced key T-cell and macrophage populations within the lamina propria, and
- Restored epithelial barrier function and mucosal architecture.
Collectively, these results establish TE205 as a potent, first-in-class MALT1 degrader with strong in vivo efficacy and clear disease-modifying potential for inflammatory bowel disease (IBD).
